Fox, E., Aplenc, R., Bagatell, R., Chuk, M. K., Dombi, E., Goodspeed, W., . . . Balis, F. M. (2010). A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. American Society of Clinical Oncology.
Citación estilo ChicagoFox, Elizabeth, et al. A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. American Society of Clinical Oncology, 2010.
Cita MLAFox, Elizabeth, et al. A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. American Society of Clinical Oncology, 2010.